Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline

QUESTIONS: Does chemotherapy—that is, gemcitabine, gemcitabine plus docetaxel, doxorubicin, or trabectedin—improve clinical outcomes in women with inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma (lms)? Is there a difference in the tumour response rate to chemotherapy be...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Gupta, A.A., Yao, X., Verma, S., Mackay, H., Hopkins, L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Multimed Inc. 2013
Aiheet:
Practice Guidelines
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3805413/
https://ncbi.nlm.nih.gov/pubmed/24155641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.20.1357
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia